tetano
Editor, Senior Moderator
Sci Adv
. 2023 Jun 16;9(24):eadf0661.
doi: 10.1126/sciadv.adf0661. Epub 2023 Jun 14. CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopes
Taishi Onodera[SUP] 1 [/SUP], Nicolas Sax[SUP] 2 [/SUP], Takashi Sato[SUP] 3 [/SUP], Yu Adachi[SUP] 1 [/SUP], Ryutaro Kotaki[SUP] 1 [/SUP], Takeshi Inoue[SUP] 4 [/SUP], Ryo Shinnakasu[SUP] 4 [/SUP], Takayuki Nakagawa[SUP] 5 [/SUP], Shuetsu Fukushi[SUP] 6 [/SUP], Tommy Terooatea[SUP] 2 [/SUP], Mai Yoshikawa[SUP] 5 [/SUP], Keisuke Tonouchi[SUP] 1 7 [/SUP], Takaki Nagakura[SUP] 1 8 [/SUP], Saya Moriyama[SUP] 1 [/SUP], Takayuki Matsumura[SUP] 1 [/SUP], Masanori Isogawa[SUP] 1 [/SUP], Kazutaka Terahara[SUP] 1 [/SUP], Tomohiro Takano[SUP] 1 [/SUP], Lin Sun[SUP] 1 [/SUP], Ayae Nishiyama[SUP] 1 [/SUP], Shinnya Omoto[SUP] 5 [/SUP], Masaharu Shinkai[SUP] 3 [/SUP], Tomohiro Kurosaki[SUP] 4 9 [/SUP], Kazuo Yamashita[SUP] 2 [/SUP], Yoshimasa Takahashi[SUP] 1 [/SUP]
Affiliations
Severe acute respiratory syndrome coronavirus 2-neutralizing antibodies primarily target the spike receptor binding domain (RBD). However, B cell antigen receptors (BCRs) on RBD-binding memory B (B[SUB]mem[/SUB]) cells have variation in the neutralizing activities. Here, by combining single B[SUB]mem[/SUB] cell profiling with antibody functional assessment, we dissected the phenotype of B[SUB]mem[/SUB] cell harboring the potently neutralizing antibodies in coronavirus disease 2019 (COVID-19)-convalescent individuals. The neutralizing subset was marked by an elevated CD62L expression and characterized by distinct epitope preference and usage of convergent V[SUB]H[/SUB] (variable region of immunoglobulin heavy chain) genes, accounting for the neutralizing activities. Concordantly, the correlation was observed between neutralizing antibody titers in blood and CD62L[SUP]+[/SUP] subset, despite the equivalent RBD binding of CD62L[SUP]+[/SUP] and CD62L[SUP]-[/SUP] subset. Furthermore, the kinetics of CD62L[SUP]+[/SUP] subset differed between the patients who recovered from different COVID-19 severities. Our B[SUB]mem[/SUB] cell profiling reveals the unique phenotype of B[SUB]mem[/SUB] cell subset that harbors potently neutralizing BCRs, advancing our understanding of humoral protection.
. 2023 Jun 16;9(24):eadf0661.
doi: 10.1126/sciadv.adf0661. Epub 2023 Jun 14. CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopes
Taishi Onodera[SUP] 1 [/SUP], Nicolas Sax[SUP] 2 [/SUP], Takashi Sato[SUP] 3 [/SUP], Yu Adachi[SUP] 1 [/SUP], Ryutaro Kotaki[SUP] 1 [/SUP], Takeshi Inoue[SUP] 4 [/SUP], Ryo Shinnakasu[SUP] 4 [/SUP], Takayuki Nakagawa[SUP] 5 [/SUP], Shuetsu Fukushi[SUP] 6 [/SUP], Tommy Terooatea[SUP] 2 [/SUP], Mai Yoshikawa[SUP] 5 [/SUP], Keisuke Tonouchi[SUP] 1 7 [/SUP], Takaki Nagakura[SUP] 1 8 [/SUP], Saya Moriyama[SUP] 1 [/SUP], Takayuki Matsumura[SUP] 1 [/SUP], Masanori Isogawa[SUP] 1 [/SUP], Kazutaka Terahara[SUP] 1 [/SUP], Tomohiro Takano[SUP] 1 [/SUP], Lin Sun[SUP] 1 [/SUP], Ayae Nishiyama[SUP] 1 [/SUP], Shinnya Omoto[SUP] 5 [/SUP], Masaharu Shinkai[SUP] 3 [/SUP], Tomohiro Kurosaki[SUP] 4 9 [/SUP], Kazuo Yamashita[SUP] 2 [/SUP], Yoshimasa Takahashi[SUP] 1 [/SUP]
Affiliations
- PMID: 37315144
- DOI: 10.1126/sciadv.adf0661
Severe acute respiratory syndrome coronavirus 2-neutralizing antibodies primarily target the spike receptor binding domain (RBD). However, B cell antigen receptors (BCRs) on RBD-binding memory B (B[SUB]mem[/SUB]) cells have variation in the neutralizing activities. Here, by combining single B[SUB]mem[/SUB] cell profiling with antibody functional assessment, we dissected the phenotype of B[SUB]mem[/SUB] cell harboring the potently neutralizing antibodies in coronavirus disease 2019 (COVID-19)-convalescent individuals. The neutralizing subset was marked by an elevated CD62L expression and characterized by distinct epitope preference and usage of convergent V[SUB]H[/SUB] (variable region of immunoglobulin heavy chain) genes, accounting for the neutralizing activities. Concordantly, the correlation was observed between neutralizing antibody titers in blood and CD62L[SUP]+[/SUP] subset, despite the equivalent RBD binding of CD62L[SUP]+[/SUP] and CD62L[SUP]-[/SUP] subset. Furthermore, the kinetics of CD62L[SUP]+[/SUP] subset differed between the patients who recovered from different COVID-19 severities. Our B[SUB]mem[/SUB] cell profiling reveals the unique phenotype of B[SUB]mem[/SUB] cell subset that harbors potently neutralizing BCRs, advancing our understanding of humoral protection.